US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced ...

Alector is kicking off a resource realignment effort that will include a workforce reduction of around 17%. The biotech ...

Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for ...

Alector’s AbbVie-partnered Alzheimer's disease asset has failed to slow disease progression in a phase 2 study, the latest in ...

南旧金山 - 专注于神经退行性疾病的生物科技公司Alector, Inc.

Alector has significant cash reserves but faces high cash burn, with no immediate catalysts and uncertain prospects for its ...

周二，高盛重申了对Alector Inc. (NASDAQ:ALEC)股票的卖出评级，维持4.00美元的目标价。关注点集中在即将公布的INVOKE-2研究的第二阶段结果，该研究正在评估Alector的AL002用于治疗阿尔茨海默病。高盛对该资产和研究提供了深入的背景分析，预览了可能的结果，并讨论了这些结果对公司估值的潜在影响。

Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter Jeffrey Hung has given his Sell rating due to a combination of factors, primarily driven by the unfavorable ...

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on ALEC stock, giving a Buy rating today.Don't Miss our Black ...

Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is ...

Alector’s internal pipeline suffered a blow as the Phase II INVOKE-2 trial evaluating its Alzheimer’s disease therapy, AL002, ...

Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment ...